ERBB2 and neoplasm: A similar approach was employed to develop an IT of Her2/neu scFv-gelonin toxin [29] and an EGFR-targeting ADC of RN765C [19] to mitigate on-target/off-tumor toxicity by modulating the affinity of the cancer antigen targeting moiety.